$ESLA News

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

Estrella Immunopharma Appoints Cynthia Pussinen CEO, Chairperson, Effective Oct. 25, Succeeding Cheng Liu

Estrella Immunopharma (ESLA) Stock Soars 18%: What’s Driving the Surge

Reported Earlier, Estrella’s EB103 Dosed Twice Three Weeks Apart In First Dose-Expansion Patient At Recommended Phase II Dose, No Treatment-Related SAEs; Dose-Escalation Delivered 100% Month 1 Complete Response In High-Dose Cohort

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

Estrella Immunopharma Q1 EPS $(0.05) Beats $(0.18) Estimate

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target